CN101502605B - Medicament composition for treating infertility and preparation method thereof - Google Patents
Medicament composition for treating infertility and preparation method thereof Download PDFInfo
- Publication number
- CN101502605B CN101502605B CN2009100795116A CN200910079511A CN101502605B CN 101502605 B CN101502605 B CN 101502605B CN 2009100795116 A CN2009100795116 A CN 2009100795116A CN 200910079511 A CN200910079511 A CN 200910079511A CN 101502605 B CN101502605 B CN 101502605B
- Authority
- CN
- China
- Prior art keywords
- portions
- subsequent use
- pharmaceutical composition
- radix
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug composition for treating infertility and a preparation method thereof. The drug composition includes the following ingredients by weight matching ratio: 0.3 to 0.9 portion of antelope horn, 15 to 45 portions of nutgrass galingale rhizome, 10 to 30 portions of American ginseng, 10 to 30 potions of white paeony root, 10 to 30 potions of Chinese angelica, 10 to 30 potions of ambir plant, 10 to 30 potions of eucommia bark, 5 to 15 portions of honey suckle flower, 5 to 15 portions of motherwort herb, 5 to 15 portions of rhizoma atractylodis, 5 to 15 portions of malaytea scurfpea fruit, 5 to 15 portions of Chinese mugwort leaf, 5 to 15 portions of szechuan lovage rhizome, 5 to 15 portions of divaricate saposhnikovia root, 5 to 15 portions of Chinese dodder seed, 5 to 15 portions of Chinese taxillus twig, 5 to 15 portions of chrysanthemum and 3 to 9 portions of liquoric root. The drug composition has the functions of tonifying the liver and kidney, replenishing qi to invigorate the spleen, nourishing yin and blood, promoting blood circulation and regulating menstruation and warming the yang and uterus, is used for treating infertility caused by spleen-Yin deficiency and kidney-Yin deficiency, liver depression and qi stagnation and deficiency of the kidney and cold uterus, and has accurate curative effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation method thereof, particularly relate to a kind of pharmaceutical composition of treating infertility and preparation method thereof, belong to the novel technique field.
Background technology
Infertility is one of gynecological's common disease.Paathogenic factor is complicated, and normal and multiple disease exists simultaneously.The generation of infertility tends to bring many injuries to patient physiological and psychology, and badly influences patient's happy family life.
The treatment by Chinese herbs infertility is with a long history; Its therapeutic effect has obtained the concern of world medical circle; Under the guidance of medical research theoretical system in modern times; Give full play to the elite of Chinese medicine treatment infertility, become the developing focus of infertility medicine with exploitation determined curative effect, the modern Chinese medicine preparation that is suitable for wide clinical application.
Summary of the invention
The object of the invention is to disclose a kind of pharmaceutical composition of treating infertility, and this pharmaceutical composition has liver and kidney tonifying, replenishing QI to invigorate the spleen, and nourishing YIN and benefiting blood, promoting blood flow to regulate menstruation, the effect in the warm palace of warming YANG is used for nourishing kidney-yin, the infertility due to the stagnation of QI due to depression of the liver, the cold womb of suffering from a deficiency of the kidney.
The present invention seeks to realize through following technical scheme:
The crude drug of pharmaceutical composition of the present invention consists of:
Cornu Saigae Tataricae 0.3～0.7 weight portion Rhizoma Cyperi 15～45 weight portion Radix Panacis Quinquefoliis 10～30 weight portions
The Radix Paeoniae Alba 10～30 weight portion Radix Angelicae Sinensis 10～30 weight portion Ramulus Uncariae Cum Uncis 10～30 weight portions
The Cortex Eucommiae 10～30 weight portion Flos Loniceraes 5～15 weight portion Herba Leonuris 5～15 weight portions
Rhizoma Atractylodis 5～15 weight portion Fructus Psoraleaes 5～15 weight portion Folium Artemisiae Argyis 5～15 weight portions
Windproof 5～15 weight portion Semen Cuscutae of Rhizoma Chuanxiong 5～15 weight portions 5～15 weight portions
Herba Taxilli 5～15 weight portion Flos Chrysanthemis 5～15 weight portion Radix Glycyrrhizaes 3～9 weight portions
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Cornu Saigae Tataricae 0.5 weight portion Rhizoma Cyperi 30 weight portion Radix Panacis Quinquefoliis 20 weight portions
The Radix Paeoniae Alba 20 weight portion Radix Angelicae Sinensis 20 weight portion Ramulus Uncariae Cum Uncis 20 weight portions
The Cortex Eucommiae 20 weight portion Flos Loniceraes 10 weight portion Herba Leonuris 10 weight portions
Rhizoma Atractylodis 10 weight portion Fructus Psoraleaes 10 weight portion Folium Artemisiae Argyis 10 weight portions
The windproof 10 weight portion Semen Cuscutae of Rhizoma Chuanxiong 10 weight portions 10 weight portions
Herba Taxilli 10 weight portion Flos Chrysanthemis 10 weight portion Radix Glycyrrhizaes 6 weight portions
Preparation of drug combination method of the present invention comprises the steps:
(1) get Cornu Saigae Tataricae, be ground into impalpable powder, subsequent use;
(2) get Rhizoma Cyperi, Radix Panacis Quinquefolii, Ramulus Uncariae Cum Uncis, Fructus Psoraleae, Rhizoma Chuanxiong, at every turn with 4-8 55%～95% ethanol extraction 1-3 time doubly, extracting solution filters, merging filtrate, and being concentrated into relative density is the thick paste of 1.30 (60 ℃), dry, pulverize, it is subsequent use to get fine powder; Medicinal residues are subsequent use;
(3) get the Radix Paeoniae Alba, Radix Angelicae Sinensis, the Cortex Eucommiae, Flos Lonicerae, Herba Leonuri, Rhizoma Atractylodis, Folium Artemisiae Argyi, windproof, Semen Cuscutae, Herba Taxilli, Flos Chrysanthemi, Radix Glycyrrhizae, merge, add water 8-16 doubly at every turn with above-mentioned medicinal residues; Decoct 1～3 time; Decocting liquid merges, and filters, and being concentrated into relative density is the thick paste of 1.30 (60 ℃); Dry, pulverizing, it is subsequent use to get fine powder;
(4) get above-mentioned fine powder,, press the conventional formulation method, add conventional pharmaceutic adjuvant, process acceptable drug dosage form clinically with Cornu Saigae Tataricae impalpable powder mixing.
Preparation of drug combination method of the present invention comprises the steps:
(1) get Cornu Saigae Tataricae, be ground into impalpable powder, subsequent use;
(2) get Rhizoma Cyperi, Radix Panacis Quinquefolii, Ramulus Uncariae Cum Uncis, Fructus Psoraleae, Rhizoma Chuanxiong, use 6 times 75% ethanol extraction 2 times at every turn, extracting solution filters, merging filtrate, being concentrated into relative density is the thick paste of 1.30 (60 ℃), dry, pulverize, fine powder is subsequent use; Medicinal residues are subsequent use;
(3) get the Radix Paeoniae Alba, Radix Angelicae Sinensis, the Cortex Eucommiae, Flos Lonicerae, Herba Leonuri, Rhizoma Atractylodis, Folium Artemisiae Argyi, windproof, Semen Cuscutae, Herba Taxilli, Flos Chrysanthemi, Radix Glycyrrhizae, merge, add 12 times of amounts of water at every turn with above-mentioned medicinal residues; Decoct 2 times; Decocting liquid merges, and filters, and being concentrated into relative density is the thick paste of 1.30 (60 ℃); Dry, pulverizing, it is subsequent use to get fine powder;
(4) get above-mentioned fine powder,, press the conventional formulation method, add conventional pharmaceutic adjuvant, process acceptable drug dosage form clinically with Cornu Saigae Tataricae impalpable powder mixing.
The pharmacodynamics test result of study proves, the increase folliculus ovarii quantity that pharmaceutical composition of the present invention has increases the endometrium area, the effect of endocrine regulation, and prompting the present invention has tangible promotion ovarian follicular growth and the effect that promotes ovulation.Following experimental example and embodiment further prove but are not limited to the present invention.
The pharmacodynamic study of medicine composite for curing kidney-deficiency type sterility of the present invention
1. the foundation of sterility due to deficiency of the kidney animal model
Make anovulation rat model (being that androgen causes infertile rat model .ASR).Get 80 of the 9th age in days female sd inbred rats (experimental group), strive ball ketone 1.25mg/ only (0.05ml/ only) in nape portion subcutaneous injection propanoic acid.The wean of the 22nd age in days utilizes natural lighting, and room temperature maintains about 20 ℃, and similarity condition is raised, and is fed by the special messenger.The 70th age in days (about the about 150g of rat body weight) vaginal opening.Continuously 2 sexual cycles of vaginal exfoliated cell smear (1 sexual cycle 5 days) vagina epithelium does not have sexual cycle and changes, prompting anovulation rat model modeling success.Equally, get 10 of the 9th age in days female sd inbred rats (normal group), in the neutral Oleum Camelliae of nape portion subcutaneous injection equivalent, to the 70th age in days vaginal opening, 2 sexual cycles of vaginal smear are observed its vaginal epithelial cell and are had or not sexual cycle to change continuously.
Observe through smear, 80 of experimental grouies are participated in the modeling rat, wherein have 54 no sexual cycles to change, and keep subsequent usely, surplus and 26 have only sexual cycle variation, rejecting.10 neutral Oleum Camelliae rats of injection of normal group all have regular sexual cycle and change, and keep subsequent use.
2. divide into groups and administration
By the random numbers table method 54 experimental group rats are divided into model group (model control group, 10), pharmaceutical composition 300mg of the present invention, 600mg, 1200mg/kg and organize (treatment group, 11 every group), clomiphene group (western medicine group, 11).Add 10 of normal control groups, experimentize.After animal divide into groups to be accomplished, since the 80th day, every day gastric infusion once, equal continuous irrigation stomach (all around) back detection in 28 days indexs.
3. collection of specimens and index detect
Each organizes continuous irrigation stomach sacrificed by decapitation all after 28 days, cuts open the belly, and takes out bilateral ovaries, uterus, observes ovary, uterus shape and writes down each item index such as ovary uterus weight.
3.1 the taking-up ovary, peeling off thousand, to put into 4% paraformaldehyde after clean fixing, dehydration of alcohols at different levels; FFPE; Section, the about 10-20um of slice thick carries out IGF-1 and MMP-9 in situ hybridization respectively; Microscope inspection and computer shooting, graphical analysis ovary IGF-1mRNA and MMP-9mRNA signal representation intensity.
3.2 take out ovary, uterus, peel off that to put into 10% formalin solution after clean fixing, dehydration of alcohols at different levels, FFPE, section, the about 5 μ m of slice thick, conventional haematoxylin, the parallel computer shooting of Yihong dyeing microscopic examination are observed ovary, uterus shape is learned and changed.
3.3 the separation jugular vein is carried pipe and got blood, centrifugal being placed in 4 ℃ of refrigerators preserved, FSH, LH content in the test serum.
4 statistical methods
The measurement data variance is used variance analysis together, and heterogeneity of variance is used rank test, and relatively with the q check, enumeration data is used X between group
2Check, all data all use SPSS 12.0 statistical softwares through Computer Processing.
5. result
5.1 influence to rat ovary, uterus
5.1.1 the gross examination of skeletal muscle in ovary, uterus
The model group ovary is pale, and follicle is seen on the surface, but the follicle number is few, and follicle is less, no corpus luteum; The uterus is less, and it is ruddy that color and luster is owed.Normal group and each dose groups of pharmaceutical composition of the present invention and Western medicine group rat ovary color and luster are scarlet, and the follicle number is obviously more than model group, and follicle obviously increases, and more corpus luteum is seen on the surface; The uterus outward appearance is thick blue, and myometrium obviously thickens.
5.1.2 ovary, uterus weight and follicle quantity, endometrium area are relatively
Each organizes ovary, uterus weight shows through the variance analysis result: compare with the normal control group, model group weight significantly reduces (p＜0.01); Big-and-middle dose groups of pharmaceutical composition of the present invention and Western medicine group weight are significantly higher than model (P＜0.01), and the big-and-middle dose groups of pharmaceutical composition of the present invention with compare no significant difference (P＞0.05) with normal group, Western medicine group.Pharmaceutical composition small dose group of the present invention also can significantly increase rat model uterus weight (p＜0.01).The result sees table 1.
Compare with the normal control group; Model group bubble number significantly reduces (p＜0.01); Big-and-middle dose groups of pharmaceutical composition of the present invention and western medicine group follicle number and model group significantly raise (p＜0.01), and the big-and-middle dose groups of pharmaceutical composition of the present invention is superior to Western medicine group (P＜0.01).Significantly reduce (p＜0.01) with the endometrium area of normal control group comparison model group; Big-and-middle dose groups of pharmaceutical composition of the present invention and western medicine group endometrium area and model group significantly raise (p＜0.01); And the big-and-middle dose groups group of pharmaceutical composition of the present invention is superior to Western medicine group (P＜0.01); Pharmaceutical composition low dose of the present invention also can significantly increase rat model follicle number and endometrium area (p＜0.01), and effect and positive drug are suitable.The result sees table 2.
Above results suggest: pharmaceutical composition of the present invention can increase sterility due to deficiency of the kidney rat ovary and uterus weight, and pharmaceutical composition of the present invention and normal group and Western medicine group be zero difference relatively; Pharmaceutical composition of the present invention can increase ovary follicle sums at different levels, and the target organ-endometrium area of ovarian hormone is obviously increased, and effect is superior to clomiphene.
The influence of table 1 pair sterility due to deficiency of the kidney rat model ovary and uterus weight
Compare with model group:
*P＜0.01.
The influence of table 2 pair sterility due to deficiency of the kidney rat model follicle quantity and endometrium area
Compare with model group:
*P＜0.01; Compare with positive drug
△P＜0.01
5.2 pharmaceutical composition of the present invention is to the endocrine influence of rat
Compare with the blank group, the level of plain FSH of model group rat serum induced ovulation and lutropin LH obviously reduces (p＜0.01).Big-and-middle dose groups of pharmaceutical composition of the present invention and western medicine group can significantly increase FSH and LH level (p＜0.01) in the animal pattern blood; And big-and-middle dose groups of pharmaceutical composition of the present invention and normal group compare zero difference (P＞0.05), and the endocrine function of pointing out pharmaceutical composition of the present invention can strengthen hypophysis promotes the synthetic of GTH and discharge to improve the pituitary gonadotropic hormone level with the growth of promotion follicle and the similar clomiphene of ovulation effect of ovary.The result sees table 3.
The influence (IU/L) of FSH and LH in the table 3 pair sterility due to deficiency of the kidney rat model blood
Compare with model group:
*P＜0.01
5.3 influence to rat ovary insulin-like growth factor-i mRNA (IGF-1mRNA) and matrix metalloproteinase-9mRNA (MMP-9mRNA) expression
Compare with the normal control group; All significantly reductions (p＜0.01) on area and the expression intensity are being expressed in the expression of model group IGF-1mRNA, and big-and-middle dosage of pharmaceutical composition of the present invention and western medicine group can significantly improve model tormulation area and expression intensity (p＜0.01); Gray value relatively in: each group of pharmaceutical composition of the present invention and Western medicine group be zero difference (P＞0.05) relatively, and each group of pharmaceutical composition of the present invention and normal group more also zero difference (P＞0.05), and the result sees table 4.Explain that pharmaceutical composition group gray value of the present invention draws close to normal group.Prompting: pharmaceutical composition of the present invention can promote the expression of ovary insulin-like growth factor-i mRNA (IGF-1mRNA) well, thereby promotes the growth of follicle and the ovulation of ovary.
Table 4 is the result also show: compare with the normal control group; All significantly increases (p＜0.01) on area and the expression intensity are being expressed in the expression of model group MMP-9mRNA; Big-and-middle dose groups of pharmaceutical composition of the present invention and western medicine group be the expression intensity and expression area (p＜0.01) of elevation model significantly; And the effect of the big-and-middle dose groups of pharmaceutical composition of the present invention is superior to positive group (P＜0.01), and still with compared with normal still variant (P＜0.01), the result sees table 5.Thereby the expression of pointing out pharmaceutical composition of the present invention can promote stroma of ovary metalloproteases-9mRNA well promotes the growth of follicle and the ovulation of ovary.
The influence that table 4 couple sterility due to deficiency of the kidney rat model ovary IGF-1mRNA expresses
Compare with model group:
*P＜0.01
The influence that table 5 couple sterility due to deficiency of the kidney rat model ovary MMP-9mRNA expresses
Compare with model group:
*P＜0.01; Compare with positive drug
△P＜0.01
6. brief summary and conclusion
In sum: pharmaceutical composition of the present invention can increase sterility due to deficiency of the kidney rat ovary and uterus weight, and effect and clomiphene are similar; Pharmaceutical composition of the present invention can increase ovary follicle sums at different levels, and the target organ-endometrium area of ovarian hormone is obviously increased, and effect is superior to clomiphene.The endocrine function that pharmaceutical composition of the present invention can strengthen hypophysis promotes the synthetic of GTH and discharges to improve the pituitary gonadotropic hormone level with the growth of promotion follicle and the ovulation of ovary, acts on similar clomiphene.Pharmaceutical composition of the present invention can promote the expression of ovary insulin-like growth factor-i mRNA (IGF-1mRNA) and matrix metalloproteinase-9mRNA (MMP-9mRNA) well, thereby promotes the growth of follicle and the ovulation of ovary.
Following embodiment all can realize the effect of above-mentioned experimental example.
Embodiment 1 medicament composition capsule agent of the present invention
Cornu Saigae Tataricae 5g, Rhizoma Cyperi 300g, Radix Panacis Quinquefolii 200g, Radix Paeoniae Alba 200g, Radix Angelicae Sinensis 200g, Ramulus Uncariae Cum Uncis 200g, Cortex Eucommiae 200g, Flos Lonicerae 100g, Herba Leonuri 100g, Rhizoma Atractylodis 100g, Fructus Psoraleae 100g, Folium Artemisiae Argyi 100g, Rhizoma Chuanxiong 100g, windproof 100g, Semen Cuscutae 100g, Herba Taxilli 100g, Flos Chrysanthemi 100g, Radix Glycyrrhizae 60g.
(1) get Cornu Saigae Tataricae powder and be broken into impalpable powder, subsequent use;
(2) get Rhizoma Cyperi, Radix Panacis Quinquefolii, Ramulus Uncariae Cum Uncis, Fructus Psoraleae, Rhizoma Chuanxiong, measure 75% ethanol with 6 times at every turn, reflux, extract, 2 times,
Each 2 hours, extract pure liquid and merge, filter, decompression recycling ethanol also is concentrated into the thick paste that relative density is 1.30 (60 ℃), dry, pulverizing, it is subsequent use to get fine powder; Medicinal residues are subsequent use;
(3) get the Radix Paeoniae Alba, Radix Angelicae Sinensis, the Cortex Eucommiae, Flos Lonicerae, Herba Leonuri, Rhizoma Atractylodis, Folium Artemisiae Argyi, windproof, Semen Cuscutae, Herba Taxilli, Flos Chrysanthemi, Radix Glycyrrhizae, merge, add 12 times of amounts of water at every turn with above-mentioned medicinal residues; Decoct 2 times, each 2 hours, decocting liquid merged; Filter; Being concentrated into relative density is the thick paste of 1.30 (60 ℃), dry, pulverizing, and it is subsequent use to get fine powder;
(4) get above-mentioned fine powder,, add 450g starch with Cornu Saigae Tataricae impalpable powder mixing, mixing, encapsulated, promptly get.
Embodiment 2 pharmaceutical composition pills of the present invention
Cornu Saigae Tataricae 3.5g, Rhizoma Cyperi 445g, Radix Panacis Quinquefolii 105g, Radix Paeoniae Alba 295g, Radix Angelicae Sinensis 105g, Ramulus Uncariae Cum Uncis 295g, Cortex Eucommiae 105g, Flos Lonicerae 145g, Herba Leonuri 145g, Rhizoma Atractylodis 145g, Fructus Psoraleae 55g, Folium Artemisiae Argyi 145g, Rhizoma Chuanxiong 55g, windproof 145g, Semen Cuscutae 145g, Herba Taxilli 55g, Flos Chrysanthemi 145g, Radix Glycyrrhizae 35g.
(1) get Cornu Saigae Tataricae, be ground into impalpable powder, subsequent use;
(2) get Rhizoma Cyperi, Radix Panacis Quinquefolii, Ramulus Uncariae Cum Uncis, Fructus Psoraleae, Rhizoma Chuanxiong, measure 90% ethanol, reflux, extract, 3 times with 8 times at every turn; Each 1 hour, extract pure liquid and merge, filter; Decompression recycling ethanol also is concentrated into the thick paste that relative density is 1.30 (60 ℃), dry, pulverizing, and it is subsequent use to get fine powder; Medicinal residues are subsequent use;
(3) get the Radix Paeoniae Alba, Radix Angelicae Sinensis, the Cortex Eucommiae, Flos Lonicerae, Herba Leonuri, Rhizoma Atractylodis, Folium Artemisiae Argyi, windproof, Semen Cuscutae, Herba Taxilli, Flos Chrysanthemi, Radix Glycyrrhizae, merge with above-mentioned medicinal residues, add 16 times of water gagings and decocted 3 hours, decocting liquid filters; Being evaporated to relative density is the thick paste of 1.30 (60 ℃), dry, pulverizing, and it is subsequent use to get fine powder;
(4) get above-mentioned fine powder,,, promptly get with water pill with Cornu Saigae Tataricae impalpable powder mixing.
Embodiment 3 medicament composition granule agent of the present invention
Cornu Saigae Tataricae 6.5g, Rhizoma Cyperi 155g, Radix Panacis Quinquefolii 295g, Ramulus Uncariae Cum Uncis 105g, Fructus Psoraleae 145g, Rhizoma Chuanxiong 145g, Radix Paeoniae Alba 105g, Radix Angelicae Sinensis 295g, Cortex Eucommiae 290g, Flos Lonicerae 55g, Herba Leonuri 145g, Rhizoma Atractylodis 55g, Folium Artemisiae Argyi 55g, windproof 55g, Semen Cuscutae 55g, Herba Taxilli 145g, Flos Chrysanthemi 55g, Radix Glycyrrhizae 85g.
(1) get Cornu Saigae Tataricae, be ground into impalpable powder, subsequent use;
(2) get Rhizoma Cyperi, Radix Panacis Quinquefolii, Ramulus Uncariae Cum Uncis, Fructus Psoraleae, Rhizoma Chuanxiong, with 4 times of amount alcohol reflux of 85% 2 times, each 2 hours; Extract pure liquid and merge, filter, decompression recycling ethanol also is concentrated into the thick paste that relative density is 1.30 (60 ℃); Dry, pulverizing, it is subsequent use to get fine powder; Medicinal residues are subsequent use;
(3) get the Radix Paeoniae Alba, Radix Angelicae Sinensis, the Cortex Eucommiae, Flos Lonicerae, Herba Leonuri, Rhizoma Atractylodis, Folium Artemisiae Argyi, windproof, Semen Cuscutae, Herba Taxilli, Flos Chrysanthemi, Radix Glycyrrhizae, merge, add 10 times of amounts of water at every turn with above-mentioned medicinal residues; Decoct 2 times, each 1 hour, decocting liquid merged; Filter; Being concentrated into relative density is the thick paste of 1.30 (60 ℃), dry, pulverizing, and it is subsequent use to get fine powder;
(4) get above-mentioned fine powder,, add sucrose and dextrin, granulate with Cornu Saigae Tataricae impalpable powder mixing, drying, granulate promptly gets.
Embodiment 4 pharmaceutical composition tablets of the present invention
Cornu Saigae Tataricae 5g, Rhizoma Cyperi 300g, Radix Panacis Quinquefolii 200g, Ramulus Uncariae Cum Uncis 200g, Fructus Psoraleae 100g, Rhizoma Chuanxiong 100g, Radix Paeoniae Alba 200g, Radix Angelicae Sinensis 200g, Cortex Eucommiae 200g, Flos Lonicerae 100g, Herba Leonuri 100g, Rhizoma Atractylodis 100g, Folium Artemisiae Argyi 100g, windproof 100g, Semen Cuscutae 100g, Herba Taxilli 100g, Flos Chrysanthemi 100g, Radix Glycyrrhizae 60g.
(1) get Cornu Saigae Tataricae, be ground into impalpable powder, subsequent use;
(2) get Rhizoma Cyperi, Radix Panacis Quinquefolii, Ramulus Uncariae Cum Uncis, Fructus Psoraleae, Rhizoma Chuanxiong, measure 80% ethanol, reflux, extract, 2 times with 6 times at every turn; Each 3 hours, extract pure liquid and merge, filter; Decompression recycling ethanol also is concentrated into the thick paste that relative density is 1.30 (60 ℃), dry, pulverizing, and it is subsequent use to get fine powder; Medicinal residues are subsequent use;
(3) get the Radix Paeoniae Alba, Radix Angelicae Sinensis, the Cortex Eucommiae, Flos Lonicerae, Herba Leonuri, Rhizoma Atractylodis, Folium Artemisiae Argyi, windproof, Semen Cuscutae, Herba Taxilli, Flos Chrysanthemi, Radix Glycyrrhizae, merge, add 14 times of amounts of water at every turn with above-mentioned medicinal residues; Decoct 2 times, each 1 hour, decocting liquid merged; Filter; Being concentrated into relative density is the thick paste of 1.30 (60 ℃), dry, pulverizing, and it is subsequent use to get fine powder;
(4) get above-mentioned fine powder,, add starch, granulate with Cornu Saigae Tataricae impalpable powder mixing, drying, granulate, tabletting promptly gets.
Claims (4)
1. pharmaceutical composition of treating infertility is characterized in that the crude drug of this pharmaceutical composition consists of:
2. pharmaceutical composition according to claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
3. like the described preparation of drug combination method of claim 1-2, it is characterized in that this method comprises the steps:
(1) get Cornu Saigae Tataricae, be ground into impalpable powder, subsequent use;
(2) get Rhizoma Cyperi, Radix Panacis Quinquefolii, Ramulus Uncariae Cum Uncis, Fructus Psoraleae, Rhizoma Chuanxiong, at every turn with 4-8 60%～95% ethanol extraction 1-3 time doubly, extracting solution filters, merging filtrate, and being concentrated into 60 ℃ of following relative densities is 1.30 thick paste, dry, pulverize, it is subsequent use to get fine powder; Medicinal residues are subsequent use;
(3) get the Radix Paeoniae Alba, Radix Angelicae Sinensis, the Cortex Eucommiae, Flos Lonicerae, Herba Leonuri, Rhizoma Atractylodis, Folium Artemisiae Argyi, windproof, Semen Cuscutae, Herba Taxilli, Flos Chrysanthemi, Radix Glycyrrhizae, merge, add water 8-16 at every turn and doubly measure with above-mentioned medicinal residues; Decoct 1～3 time; Decocting liquid merges, and filters, and being concentrated into 60 ℃ of following relative densities is 1.30 thick paste; Dry, pulverizing, it is subsequent use to get fine powder;
(4) get above-mentioned fine powder,, press the conventional formulation method, add conventional pharmaceutic adjuvant, process acceptable drug dosage form clinically with Cornu Saigae Tataricae impalpable powder mixing.
4. preparation of drug combination method as claimed in claim 3 is characterized in that this method comprises the steps:
(1) get Cornu Saigae Tataricae, be ground into impalpable powder, subsequent use;
(2) get Rhizoma Cyperi, Radix Panacis Quinquefolii, Ramulus Uncariae Cum Uncis, Fructus Psoraleae, Rhizoma Chuanxiong, use 6 times 75% ethanol extraction 2 times at every turn, extracting solution filters, merging filtrate, being concentrated into 60 ℃ of following relative densities is 1.30 thick paste, dry, pulverize, fine powder is subsequent use; Medicinal residues are subsequent use;
(3) get the Radix Paeoniae Alba, Radix Angelicae Sinensis, the Cortex Eucommiae, Flos Lonicerae, Herba Leonuri, Rhizoma Atractylodis, Folium Artemisiae Argyi, windproof, Semen Cuscutae, Herba Taxilli, Flos Chrysanthemi, Radix Glycyrrhizae, merge, add 12 times of amounts of water at every turn with above-mentioned medicinal residues; Decoct 2 times; Decocting liquid merges, and filters, and being concentrated into 60 ℃ of following relative densities is 1.30 thick paste; Dry, pulverizing, it is subsequent use to get fine powder;
(4) get above-mentioned fine powder,, press the conventional formulation method, add conventional pharmaceutic adjuvant, process acceptable drug dosage form clinically with Cornu Saigae Tataricae impalpable powder mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100795116A CN101502605B (en) | 2009-03-06 | 2009-03-06 | Medicament composition for treating infertility and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100795116A CN101502605B (en) | 2009-03-06 | 2009-03-06 | Medicament composition for treating infertility and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101502605A CN101502605A (en) | 2009-08-12 |
| CN101502605B true CN101502605B (en) | 2012-05-02 |
Family
ID=40975068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100795116A Expired - Fee Related CN101502605B (en) | 2009-03-06 | 2009-03-06 | Medicament composition for treating infertility and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101502605B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055930A (en) * | 2015-07-21 | 2015-11-18 | 张泽花 | Traditional Chinese medicine for treating infertility caused by liver stagnation and preparation method of traditional Chinese medicine |
| CN105012804A (en) * | 2015-08-05 | 2015-11-04 | 张梅芳 | Traditional Chinese medicine for treating turbid-phlegm type infertility and preparation method of traditional Chinese medicine |
| CN109620951A (en) * | 2018-12-28 | 2019-04-16 | 丽睿客信息科技（北京）有限公司 | One kind helping pregnant composition and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1175456A (en) * | 1997-09-10 | 1998-03-11 | 陈二民 | Traditional Chinese medicine composition for treatment of female dysgenesis |
| CN1526439A (en) * | 2003-09-23 | 2004-09-08 | 邢文照 | Chinese medicine for treating women's sterility and its prepn and use |
-
2009
- 2009-03-06 CN CN2009100795116A patent/CN101502605B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1175456A (en) * | 1997-09-10 | 1998-03-11 | 陈二民 | Traditional Chinese medicine composition for treatment of female dysgenesis |
| CN1526439A (en) * | 2003-09-23 | 2004-09-08 | 邢文照 | Chinese medicine for treating women's sterility and its prepn and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101502605A (en) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102716417B (en) | Traditional Chinese medicine preparation for treating gynaecopathia and preparation method of preparation | |
| CN1723926A (en) | Traditional Chinese medicine liquor and preparation method thereof | |
| CN103071019B (en) | Menstruation regulating and pregnancy assisting medicine, preparation technology and application of medicine | |
| CN104547579A (en) | Medicine composition for treating hyperprolactinemia infertility and application of medicine composition | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN1806840B (en) | Chinese medicinal compound preparation and its preparing process | |
| CN104258066A (en) | Traditional Chinese medicine preparation for treating kidney-yin deficiency-type dysfunctional uterine bleeding, and preparation method thereof | |
| CN102813857A (en) | Chinese herbal Siyu blood-tonifying and kidney-nourishing preparation | |
| CN101502605B (en) | Medicament composition for treating infertility and preparation method thereof | |
| CN104258292A (en) | Drug for department of obstetrics and gynecology for treating pregnancy complication and manufacturing method thereof | |
| CN107802733B (en) | Kidney-tonifying and fetus-cultivating traditional Chinese medicine composition and application thereof | |
| CN101991814A (en) | Preparation with functions of expelling wind, reducing phlegm, promoting blood circulation and removing obstruction from channels and preparation method | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN102114070B (en) | Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof | |
| CN101856431B (en) | Medicament for treating liver-kidney yin deficiency type anovulatory dysfunctional uterine bleeding, and preparation method and application thereof | |
| CN102048841A (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN102293923A (en) | Application of Tibetan medicinal composition to preparation of medicament for preventing and treating osteoporosis | |
| CN113209223A (en) | Traditional Chinese medicine composition for treating ovulation failure infertility and preparation method thereof | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN111588790B (en) | Chinese medicinal compound medicine for improving gynecological reproductive and endocrine diseases and preparation method thereof | |
| CN111388584A (en) | Composition for treating impotence and preparation method thereof | |
| CN114432410B (en) | Blood circulation promoting and stasis removing paste formula and application thereof | |
| CN111905022B (en) | Medicine for promoting ovulation and preparation method thereof | |
| CN116036162B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof | |
| CN1240421C (en) | Specific medicine for curing diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120502 Termination date: 20180306 |